Zimvie

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Westminster, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ZimVie reports Q4 decline, focuses on innovation and challenges

ZimVie's Q4 2022 performance reflected challenges from disruptions in China and spine segment, leading to a decline in net sales.
Despite these challenges, the company showed strength in product innovation, operational efficiencies, and strategic partnerships.
Opportunities lie in focusing on growth through innovation, commercial success, and addressing challenges to improve performance.

ZimVie reports mixed Q1 performance, revises 2023 outlook upwards

ZimVie's Q1 2023 earnings call highlighted a mixed performance with a focus on innovation, financial discipline, and growth potential. While facing challenges in revenue generation and margins, the company's strategic approach and revised outlook indicate opportunities for market expansion and sustained growth.

ZimVie reports strong Q2 earnings, eyes growth in international markets

ZimVie's Q2 2023 earnings call highlighted robust financial performance, strategic initiatives in innovation, and growth prospects in dental and spine segments. The company aims to navigate competitive pressures, capitalize on market trends, and drive profitability through operational efficiencies and product differentiation.

ZimVie reports mixed Q3 results, focuses on innovation and efficiency

ZimVie's Q3 2023 performance reflected mixed results with growth in international dental sales but challenges in the U.S. and spine segments.
Operational efficiency improvements and cash position enhancement are strengths for the company.
Challenges include competition in spine, declining U.S. dental sales, and margin decline, while opportunities lie in market trends and strategic deals.

ZimVie sells spine business for $375 million, targets profitability

ZimVie's Q4 2023 performance reflects a strategic shift towards enhancing profitability through the sale of the spine business and cost optimization initiatives. While facing challenges in market conditions and debt reduction targets, the company aims to capitalize on opportunities for growth and improved financial health.

ZimVie focuses on dental business post-sale, eyes margin growth

ZimVie's Q1 2024 performance reflected a strategic shift towards the dental segment post-spine business sale.
While facing challenges in revenue generation and margin targets, the company's focus on efficiency and innovation bodes well for future growth.
Opportunities lie in margin improvement, market expansion, and new revenue streams through innovative dental solutions.

ZimVie reports robust Q2 revenue, eyes growth amidst short-term challenges

ZimVie's Q2 2024 performance showcased revenue growth and strong commercial traction in key portfolios
Despite short-term revenue challenges, the company reaffirmed full-year guidance and highlighted growth opportunities
Strategic partnerships and product advancements position ZimVie for continued market expansion and innovation
Maintaining financial discipline and focus on profitability amidst market dynamics are key priorities

ZimVie reports solid Q3 earnings, eyes North America for growth

ZimVie's Q3 performance showcased financial stability, strategic investments, and growth in key product portfolios. While challenges like debt management persist, the company's focus on efficiency and innovation positions them well for future opportunities in the dental market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Palm Beach Gardens, FL.

WESTMINSTER, Colo., Aug. 29, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will participate in Morgan Stanley's 20th Annual Global Healthcare Conference held in New York, New York.

ZimVie to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

ZimVie was spun out of Zimmer Biomet in early March. The company recently reported disappointing Q2 results with weak revenues and poor guidance.

ZimVie: Disappointing Guidance Prompts Caution

Investors didn't like the company's guidance cut.

Why ZimVie Stock Is Sinking Today

ZimVie Inc. (NASDAQ:ZIMV ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Operator Good day and thank you for standing by. Welcome to the ZimVie's Second Quarter 2022 Earnings Call.

ZimVie Inc. (ZIMV) CEO Vafa Jamali on Q2 2022 Results - Earnings Call Transcript

WESTMINSTER, Colo., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call today, August 10, 2022, at 4:30 p.m. Eastern Time.

ZimVie Reports Second Quarter 2022 Financial Results

WESTMINSTER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10, 2022. Company management will host a corresponding audio webcast beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Second Quarter 2022 Financial Results on August 10, 2022

ZimVie was spun out of Zimmer Biomet in March. Stock came under significant selling pressure From Day 1 due to technical factors.

ZimVie: Undervalued Spin-Off

T3® PRO Tapered Implant and the Encode® Emergence Healing Abutment designed to optimize restorative care and aesthetics T3® PRO Tapered Implant and the Encode® Emergence Healing Abutment designed to optimize restorative care and aesthetics

ZimVie Announces Launch of Two Next-Generation Dental Solutions in the United States

Brookfield Business Corp

Constellation Energy Corp

Embecta Corp

ESAB Corp

Spinoffs are known for being a mixed bag from the investor's viewpoint. Some of them can unlock the true value of businesses by allowing them to focus on their niches rather than being hampered by underinvestment and undervaluation as part of a bulkier corporation.

Spinoffs Roundup: These Companies Could Unlock Value in 2022

ZimVie Inc. (NASDAQ:ZIMV ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Matt Miksic - Credit Suisse Operator Good afternoon and welcome to ZimVie's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

ZimVie Inc. (ZIMV) CEO Vafa Jamali on Q1 2022 Results - Earnings Call Transcript

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the quarter ended March 31, 2022. Management will host a corresponding conference call today, May 5, 2022 at 4:30 p.m. Eastern Time.

ZimVie Reports First Quarter 2022 Financial Results

ZimVie is a spin-off of the dental and spine business units of Zimmer Biomet. The Company is a leading player with #5 and #6 positions in the dental and spine market respectively.

ZimVie: Spin-Off Of Dental And Spine Units Of Zimmer Biomet

WESTMINSTER, Colo., April 12, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report First Quarter 2022 Financial Results on May 5, 2022

WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the three months and full year ended December 31, 2021.

ZimVie Reports 2021 Financial Results, Reaffirms 2022 Financial Guidance, and Provides Supplemental Financial Information

WESTMINSTER, Colo., March 01, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV) today announced its debut as an independent publicly traded company and the completion of its separation from Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH). This separation completes the path ZimVie began in 2021 when its former parent company announced its intention to separate its Dental and Spine businesses into one of the world's newest and leading life sciences companies. ZimVie common stock began “regular way” trading under the symbol “ZIMV” on the Nasdaq Stock Market.

News for Zimvie Stock (ZIMV)